Literature DB >> 24531856

Association of interleukin 1 family with systemic sclerosis.

Li Zhang1, Jun-Wei Yan, Yu-Jie Wang, Ya-Nan Wan, Bing-Xiang Wang, Jin-Hui Tao, Bing Chen, Bao-Zhu Li, Guo-Jun Yang, Jing Wang.   

Abstract

Systemic sclerosis is a connective tissue disease characterized with fibrosis of skin and/or internal organs, and its specific pathological mechanism remains incompletely understood. IL-1 family, whose biological properties are typically pro-inflammatory and pro-fibrosis, has been associated with systemic sclerosis (SSc). Interleukin (IL)-1 family has 11 members, IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37, and IL-38. With the exception of IL-1Ra and IL-36Ra, each member has its own receptor signal. Abnormal expression of IL-1 and its potential role in the fibrosis process have been probed earliest, as well as its gene polymorphisms with SSc. IL-33 and IL-18 have also been discussed in the recent years, and IL-33 may contribute to the fibrosis of SSc, while IL-18 remains to be researched to confirm its role in fibrosis process. There is a lack of studies on the association of the other members of the IL-1 family, which might provide us the future study area; much more efforts need to be put on this matter.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531856     DOI: 10.1007/s10753-014-9848-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  54 in total

1.  Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts.

Authors:  Yasushi Kawaguchi; Emi Nishimagi; Akiko Tochimoto; Manabu Kawamoto; Yasuhiro Katsumata; Makoto Soejima; Tokiko Kanno; Naoyuki Kamatani; Masako Hara
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

2.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

Review 3.  Biology of IL-36 cytokines and their role in disease.

Authors:  Mark S Gresnigt; Frank L van de Veerdonk
Journal:  Semin Immunol       Date:  2013-12-17       Impact factor: 11.130

4.  Defective production of leucocytic endogenous mediator (interleukin 1) by peripheral blood leucocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease.

Authors:  J T Whicher; A M Gilbert; C Westacott; C Hutton; P A Dieppe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

5.  The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Authors:  Carol M Artlett; Sihem Sassi-Gaha; Judy L Rieger; Alina C Boesteanu; Carol A Feghali-Bostwick; Peter D Katsikis
Journal:  Arthritis Rheum       Date:  2011-11

6.  [A case of recurrent hemophagocytic syndrome complicated with systemic sclerosis: relationship between disease activity and serum level of IL-18].

Authors:  A Tochimoto; E Nishimagi; Y Kawaguchi; T Kobashigawa; H Okamoto; M Harigai; C Terai; M Hara; N Kamatani
Journal:  Ryumachi       Date:  2001-06

7.  Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis.

Authors:  T Yamamoto; Y Sawada; I Katayama; K Nishioka
Journal:  Br J Rheumatol       Date:  1998-10

8.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.

Authors:  Hangjun Duan; Jo Fleming; David K Pritchard; Lynn M Amon; Jun Xue; Heather A Arnett; Guang Chen; Patricia Breen; Jane H Buckner; Jerry A Molitor; Keith B Elkon; Stephen M Schwartz
Journal:  Arthritis Rheum       Date:  2008-05

Review 9.  Association of interleukin-18 (-137G/C) polymorphism with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis.

Authors:  Dan Wen; Jun Liu; Xin Du; Jian-Zeng Dong; Chang-Sheng Ma
Journal:  Int Rev Immunol       Date:  2013-08-05       Impact factor: 5.311

10.  Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis.

Authors:  Yasushi Kawaguchi; Masako Hara; Naoyuki Kamatani; Timothy M Wright
Journal:  Arthritis Rheum       Date:  2003-01
View more
  8 in total

Review 1.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

2.  Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: an independent case-control study and a meta-analysis.

Authors:  Xiao-Lei Huang; Guo-Cui Wu; Yu-Jie Wang; Xiao-Ke Yang; Guo-Jun Yang; Jin-Hui Tao; Yu Duan; Jun-Wei Yan; Xiang-Pei Li; Dong-Qing Ye; Jing Wang
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

4.  Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis.

Authors:  Emily Lin; Fabien B Vincent; Joanne Sahhar; Gene-Siew Ngian; Rangi Kandane-Rathnayake; Rachel Mende; Eric F Morand; Tali Lang; James Harris
Journal:  Clin Transl Immunology       Date:  2019-04-06

5.  Pirfenidone activates cannabinoid receptor 2 in a mouse model of bleomycin-induced pulmonary fibrosis.

Authors:  Jinhong Liu; Guiling Shi
Journal:  Exp Ther Med       Date:  2019-09-25       Impact factor: 2.447

6.  IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis.

Authors:  Anna Birnhuber; Slaven Crnkovic; Valentina Biasin; Leigh M Marsh; Balazs Odler; Anita Sahu-Osen; Elvira Stacher-Priehse; Luka Brcic; Frank Schneider; Nada Cikes; Bahil Ghanim; Walter Klepetko; Winfried Graninger; Yannick Allanore; Robert Eferl; Andrea Olschewski; Horst Olschewski; Grazyna Kwapiszewska
Journal:  Eur Respir J       Date:  2019-09-29       Impact factor: 16.671

Review 7.  Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.

Authors:  Abdolreza Esmaeilzadeh; Nazila Bahmaie; Elham Nouri; Mohammad Javad Hajkazemi; Maryam Zareh Rafie
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

8.  Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.

Authors:  Kazuki Takada; Tatsuro Okamoto; Masaki Tominaga; Koji Teraishi; Takaki Akamine; Shinkichi Takamori; Masakazu Katsura; Gouji Toyokawa; Fumihiro Shoji; Masaki Okamoto; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.